Published in Hum Gene Ther on April 11, 2011
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J Gen Virol (2012) 1.34
Functional cloning of recurrence-specific antigens identifies molecular targets to treat tumor relapse. Mol Ther (2013) 1.16
Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer. Cancer Res (2012) 1.10
Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters. PLoS One (2013) 1.08
Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat Med (2013) 1.07
Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J Virol (2011) 1.04
Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape. Hum Gene Ther (2012) 0.99
Vesicular stomatitis virus expressing tumor suppressor p53 is a highly attenuated, potent oncolytic agent. J Virol (2011) 0.88
The profile of tumor antigens which can be targeted by immunotherapy depends upon the tumor's anatomical site. Mol Ther (2014) 0.86
The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control. Mol Ther (2014) 0.85
Chemotherapy and Oncolytic Virotherapy: Advanced Tactics in the War against Cancer. Front Oncol (2014) 0.85
Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity. J Virol (2012) 0.85
Oncolytic virus-mediated reversal of impaired tumor antigen presentation. Front Oncol (2014) 0.85
Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors. J Virol (2015) 0.84
Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation. J Virol (2011) 0.84
Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Hum Gene Ther (2015) 0.83
Inhibitory Receptors Induced by VSV Viroimmunotherapy Are Not Necessarily Targets for Improving Treatment Efficacy. Mol Ther (2017) 0.82
Replicating viral vectors for cancer therapy: strategies to synergize with host immune responses. Microb Biotechnol (2011) 0.82
Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco Targets Ther (2016) 0.81
Sorting Out Pandora's Box: Discerning the Dynamic Roles of Liver Microenvironment in Oncolytic Virus Therapy for Hepatocellular Carcinoma. Front Oncol (2014) 0.80
Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines (2017) 0.79
Oncolytic Vesicular Stomatitis Virus as a Viro-Immunotherapy: Defeating Cancer with a "Hammer" and "Anvil". Biomedicines (2017) 0.79
Oncolytic Immunotherapy: Conceptual Evolution, Current Strategies, and Future Perspectives. Front Immunol (2017) 0.79
The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice. Mol Ther (2012) 0.78
Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy. Int J Radiat Oncol Biol Phys (2015) 0.78
Murine Tumor Models for Oncolytic Rhabdo-Virotherapy. ILAR J (2016) 0.77
Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma. J Virol (2013) 0.77
Ovarian cancer treatment with a tumor-targeting and gene expression-controllable lipoplex. Sci Rep (2016) 0.76
The Effect of Vector Silencing during Picornavirus Vaccination against Experimental Melanoma and Glioma. PLoS One (2016) 0.75
Oncolytic Virotherapy: A Contest between Apples and Oranges. Mol Ther (2017) 0.75
Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain. J Virol (2017) 0.75
T cell receptor antagonist peptides induce positive selection. Cell (1994) 18.66
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J Exp Med (2003) 11.08
Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer (2008) 9.82
Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A (1995) 9.08
Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med (1988) 8.90
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A (2002) 8.72
Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J Exp Med (2005) 8.13
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer (2003) 4.99
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responses. Proc Natl Acad Sci U S A (2006) 2.72
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol (2002) 2.44
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res (2008) 2.15
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther (2007) 2.14
A melanocyte-specific gene, Pmel 17, maps near the silver coat color locus on mouse chromosome 10 and is in a syntenic region on human chromosome 12. Proc Natl Acad Sci U S A (1991) 1.97
Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst (2002) 1.56
Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther (2010) 1.51
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother (1997) 1.47
Potentiating cancer immunotherapy using an oncolytic virus. Mol Ther (2010) 1.46
Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol (2006) 1.44
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther (2008) 1.34
Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma. Gene Ther (2009) 1.30
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol (2009) 1.25
Making room for T cells. J Clin Invest (2002) 1.19
Recombinant Newcastle disease virus as a vaccine vector for cancer therapy. Mol Ther (2008) 1.16
VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol Ther (2010) 1.15
Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus. Hum Gene Ther (2010) 1.15
Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum Gene Ther (2010) 1.14
Engineering T cells for cancer therapy. Br J Cancer (2005) 1.05
Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther (2010) 1.03
Enhancing the therapeutic effect against ovarian cancer through a combination of viral oncolysis and antigen-specific immunotherapy. Mol Ther (2010) 1.01
Treg depletion-enhanced IL-2 treatment facilitates therapy of established tumors using systemically delivered oncolytic virus. Mol Ther (2008) 1.00
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy. J Leukoc Biol (1996) 0.98
Cloning, expression and tissue distribution of the murine homologue of the melanocyte lineage-specific antigen gp100. Melanoma Res (1997) 0.97
Synergy of adoptive T-cell therapy and intratumoral suicide gene therapy is mediated by host NK cells. Gene Ther (2007) 0.92
T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy. Clin Cancer Res (2010) 0.91
Oncolytic herpes simplex virus armed with xenogeneic homologue of prostatic acid phosphatase enhances antitumor efficacy in prostate cancer. Gene Ther (2010) 0.90
A promising cancer gene therapy agent based on the matrix protein of vesicular stomatitis virus. FASEB J (2008) 0.84
Nonrandom processes maintain diversity in tropical forests. Science (2006) 3.86
Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors. Nat Med (2011) 3.60
Assessing evidence for a pervasive alteration in tropical tree communities. PLoS Biol (2008) 3.58
Oncolytic immunovirotherapy for melanoma using vesicular stomatitis virus. Cancer Res (2007) 2.72
A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol (2004) 2.39
Testing metabolic ecology theory for allometric scaling of tree size, growth and mortality in tropical forests. Ecol Lett (2006) 2.36
The influence of spatial and size scale on phylogenetic relatedness in tropical forest communities. Ecology (2007) 2.26
A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18
Comparing tropical forest tree size distributions with the predictions of metabolic ecology and equilibrium models. Ecol Lett (2006) 2.17
The problem and promise of scale dependency in community phylogenetics. Ecology (2006) 2.13
The 'human revolution' in lowland tropical Southeast Asia: the antiquity and behavior of anatomically modern humans at Niah Cave (Sarawak, Borneo). J Hum Evol (2006) 2.07
Tumor-targeted, systemic delivery of therapeutic viral vectors using hitchhiking on antigen-specific T cells. Nat Med (2005) 2.04
Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91
High-level vancomycin-resistant Staphylococcus aureus isolates associated with a polymicrobial biofilm. Antimicrob Agents Chemother (2006) 1.77
Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med (2007) 1.74
Cell carriers for oncolytic viruses: Fed Ex for cancer therapy. Mol Ther (2009) 1.72
Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70
A conditionally replicating adenovirus targeted to tumor cells through activated RAS/P-MAPK-selective mRNA stabilization. Nat Biotechnol (2003) 1.58
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma. Nat Biotechnol (2012) 1.52
Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50
Tumor antigen-specific induction of transcriptionally targeted retroviral vectors from chimeric immune receptor-modified T cells. Nat Biotechnol (2002) 1.48
Initiation factor IF2, thiostrepton and micrococcin prevent the binding of elongation factor G to the Escherichia coli ribosome. J Mol Biol (2002) 1.46
Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med (2012) 1.46
CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors. Mol Ther Nucleic Acids (2013) 1.45
Tumor infection by oncolytic reovirus primes adaptive antitumor immunity. Clin Cancer Res (2008) 1.44
Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res (2002) 1.42
Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer. Cancer Res (2007) 1.37
Trait similarity, shared ancestry and the structure of neighbourhood interactions in a subtropical wet forest: implications for community assembly. Ecol Lett (2010) 1.36
Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res (2005) 1.35
Advances in the use of DNA barcodes to build a community phylogeny for tropical trees in a Puerto Rican forest dynamics plot. PLoS One (2010) 1.35
Temporal turnover in the composition of tropical tree communities: functional determinism and phylogenetic stochasticity. Ecology (2012) 1.31
Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer. Cancer Res (2010) 1.27
Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma. Cancer Res (2009) 1.27
The biology of the sodium iodide symporter and its potential for targeted gene delivery. Curr Cancer Drug Targets (2010) 1.25
Short-course radiotherapy, with elective delay prior to surgery, in patients with unresectable rectal cancer who have poor performance status or significant co-morbidity. Radiother Oncol (2009) 1.25
Thiostrepton-resistant mutants of Thermus thermophilus. Nucleic Acids Res (2004) 1.24
CTFS-ForestGEO: a worldwide network monitoring forests in an era of global change. Glob Chang Biol (2014) 1.24
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22
Killing of normal melanocytes, combined with heat shock protein 70 and CD40L expression, cures large established melanomas. J Immunol (2006) 1.20
Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates. Hum Gene Ther (2010) 1.18
Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer. BMC Cancer (2011) 1.17
Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17
Expression of the CUB domain containing protein 1 (CDCP1) gene in colorectal tumour cells. FEBS Lett (2007) 1.16